top of page

BackTable / Tumor Board / Podcast / Episode #47

NSCLC Treatment: Bispecific Antibodies & EGFR Mutations

with Dr. Wade Iams

Bispecific antibodies are emerging as an important therapeutic class in non-small cell lung cancer (NSCLC); but how do they work, where do they fit in clinical practice, and what should oncologists be thinking about next? In this episode of Back Table Tumor Board, Dr. Kate Baker and Dr. Wade Iams from Tennessee Oncology answer these questions and more.

Be part of the conversation. Put your sponsored messaging on this episode. Learn how.

NSCLC Treatment: Bispecific Antibodies & EGFR Mutations with Dr. Wade Iams on the BackTable Tumor Board Podcast
Ep 47 NSCLC Treatment: Bispecific Antibodies & EGFR Mutations with Dr. Wade Iams
00:00 / 01:04

BackTable, LLC (Producer). (2026, February 10). Ep. 47 – NSCLC Treatment: Bispecific Antibodies & EGFR Mutations [Audio podcast]. Retrieved from https://www.backtable.com

Stay Up To Date

Follow:

Subscribe:

Sign Up:

Podcast Contributors

Dr. Kate Baker on the BackTable Tumor Board Podcast

Dr. Kate Baker is a medical oncologist and Medical Director of Value-Based Care at Tennessee Oncology.

Dr. Wade Iams on the BackTable Tumor Board Podcast

Dr. Wade Iams is a medical oncologist practicing at Tennessee Oncology in Nashville, Tennessee.

Synopsis

Dr. Baker and Dr. Iams discuss the evolving role of bispecific antibodies in NSCLC, covering the clinical data behind amivantamab, the practical benefits of subcutaneous vs IV administration, and key considerations for managing unique bispecific-related toxicities in real-world practice. This episode also explores emerging data in NSCLC, highlighting tarlatamab and its promising results in various treatment scenarios, including potential earlier-stage applications.

Timestamps

00:00 - Introduction
01:14 - Recent Developments in Bispecific Antibodies
03:24 - Real-World Application of MARIPOSA Trial Data
04:28 - Managing Toxicities and Side Effects
06:28 - CNS Disease and Efficacy of Combination Therapy
08:26 - Counseling Patients on Prognosis and Treatment Options
12:45 - Challenges in Rolling Out New Treatments in Rural Areas
18:21- Future Directions in Non-Small Cell Lung Cancer
20:57 - BiTE Therapies in Small Cell Lung Cancer
35:00 - Final Thoughts

Resources

The Materials available on BackTable are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

backtable-plus-vi-cta.jpg
Become a BackTable Sponsor

Up Next

Pulse Electrical Field Ablation: Lung Cancer Applications & Benefits with Dr. William Moore and Dr. Daniel Sterman on the BackTable Tumor Board Podcast
Urothelial Carcinoma: Understanding ctDNA & Precision Medicine with Dr. Amanda Nizam and Dr. Brad McGregor on the BackTable Tumor Board Podcast
ESMO Update: Advances in Upper GI Malignancies with Dr. Jun Gong and Dr. Jonathan Mizrahi on the BackTable Tumor Board Podcast
ESMO Update: Trial Results & New Therapies in Colorectal Cancer with Dr. Jun Gong and Dr. Jonathan Mizrahi on the BackTable Tumor Board Podcast
Neoadjuvant Therapy in Resectable Pancreatic Cancer with Dr. Rebecca Snyder and Dr. Jonathan Mizrahi on the BackTable Tumor Board Podcast
Complex HCC Patients & The "Grey Zone": What To Do When You Don’t Know What To Do with Dr. Adam Burgoyne, Dr. Zach Berman, Dr. Kirema Garcia-Reyes and Dr. Lingling Du on the BackTable Tumor Board Podcast

Articles

Topics

Get in touch!

We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.

bottom of page